At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Lenalidomidedrug
Likely dose
Lenalidomide 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia Age 65 or Older.
In Brief
A Phase 2 clinical trial evaluating Lenalidomide for Leukemia and 3 related conditions. Completed, enrolled 61 participants across 1 site.
Detailed Summary
Primary Objective: * To assess the activity of lenalidomide in patients with previously untreated chronic lymphocytic leukemia (CLL) age 65 and older. Secondary Objective: * To assess the tolerability of lenalidomide in patients with untreated CLL age 65 and older
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsCelgene
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2007
Enrollment StartOct 2007
Primary CompletionFeb 2013
TodayJul 2026
First PostedSep 26, 2007
Enrollment StartOct 1, 2007
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.8 years ago
Interventions
Lenalidomidedrug
Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.